Susheel Perikala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susheel Perikala has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Dimitrios N. Sidiropoulos
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
24 shared publications - Dmitrijs Lvovs
Institute for Genome Sciences, University of Maryland, Baltimore, MD
24 shared publications - Elana Judith Fertig
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
24 shared publications - Elizabeth M. Jaffee
Johns Hopkins Convergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
24 shared publications - James M. Leatherman
Sidney Kimmel Comprehensive Cancer Center 8 Baltimore, MD
24 shared publications - Ludmila Danilova
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA
24 shared publications
Latest Publications
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 5. Effects of adding αPD1 to GVAX on myeloid cells.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 5. Effects of adding αPD1 to GVAX on myeloid cells.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 1. Peripheral blood samples were collected from patients participating in three clinical trials, both before and after two cycles of treatment.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 1. Peripheral blood samples were collected from patients participating in three clinical trials, both before and after two cycles of treatment.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 2. Directly Analyzable Immune Profile Atlas.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 2. Directly Analyzable Immune Profile Atlas.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 3. Effects of GVAX on T helper cells and myeloid cells.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 3. Effects of GVAX on T helper cells and myeloid cells.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 7. Comparison between GVAX and CRS207 in combination with αPD1 and αCTLA4.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 7. Comparison between GVAX and CRS207 in combination with αPD1 and αCTLA4.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 6. Effects of GVAX+αCTLA4 on T cell activation.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 6. Effects of GVAX+αCTLA4 on T cell activation.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-4 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Table 1. Number of samples per trial arm, timepoints, and clinical metadata. SD: Stable Disease, PD: Progressive Disease, PR: Partial response. Supplementary Table 2. T cell focused CyTOF Panel. Supplementary Table 3. Myeloid CyTOF Panel. Supplementary Table 4. IMC Panel.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-4 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Table 1. Number of samples per trial arm, timepoints, and clinical metadata. SD: Stable Disease, PD: Progressive Disease, PR: Partial response. Supplementary Table 2. T cell focused CyTOF Panel. Supplementary Table 3. Myeloid CyTOF Panel. Supplementary Table 4. IMC Panel.
- Open Access
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 4. Effects of GVAX on T helper cells and myeloid cells. Impact of anti–PD-1 therapy (αPD1) when added to GVAX on T cells.
- 4 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Supplementary Figure 4. Effects of GVAX on T helper cells and myeloid cells. Impact of anti–PD-1 therapy (αPD1) when added to GVAX on T cells.
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (3) , 399-410
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Combination vaccine and checkpoint inhibitor therapy has previously demonstrated immunologic responses in patients with pancreatic ductal adenocarcinoma (PDAC), although with limited efficacy. An urgent need to augment responses has warranted a deeper understanding of how each treatment modality contributes to the overall inflammatory response. Serial blood samples from patients with PDAC treated with GVAX, CRS-207, anti–CTLA-4, and/or anti–PD-1 therapies were profiled using two mass cytometry panels. Generating 260 cytometric profiles from 64 unique patients allowed us to create an annotated PDAC immunotherapy atlas. Analysis of this atlas revealed that although GVAX alone did not significantly alter T-cell relative frequencies, it induced T-cell activation and upregulated checkpoint expression. Adding anti–PD-1 blockade to GVAX further enhanced T-cell activation, whereas adding anti–CTLA-4 distinctly enhanced memory formation. Vaccine-mediated effects were similar, but GVAX promoted plasmacytoid dendritic cells more than CRS-207. Derived phenotypic patterns could also be projected onto tumor imaging data, underscoring the potential for discoveries relating treatment-induced peripheral signatures to changes in the tumor microenvironment. See related article by Bever et al., p. 411
- 12 January 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 14 (3) , 399-410
Cytometric Atlas of Combination Immunotherapy in Pancreatic Cancer: Blood-Based Signatures Reveal Vaccine and Checkpoint Inhibitor Responses
Combination vaccine and checkpoint inhibitor therapy has previously demonstrated immunologic responses in patients with pancreatic ductal adenocarcinoma (PDAC), although with limited efficacy. An urgent need to augment responses has warranted a deeper understanding of how each treatment modality contributes to the overall inflammatory response. Serial blood samples from patients with PDAC treated with GVAX, CRS-207, anti–CTLA-4, and/or anti–PD-1 therapies were profiled using two mass cytometry panels. Generating 260 cytometric profiles from 64 unique patients allowed us to create an annotated PDAC immunotherapy atlas. Analysis of this atlas revealed that although GVAX alone did not significantly alter T-cell relative frequencies, it induced T-cell activation and upregulated checkpoint expression. Adding anti–PD-1 blockade to GVAX further enhanced T-cell activation, whereas adding anti–CTLA-4 distinctly enhanced memory formation. Vaccine-mediated effects were similar, but GVAX promoted plasmacytoid dendritic cells more than CRS-207. Derived phenotypic patterns could also be projected onto tumor imaging data, underscoring the potential for discoveries relating treatment-induced peripheral signatures to changes in the tumor microenvironment. See related article by Bever et al., p. 411